📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study (2023)

First Author: Liu Z

Attributed to: 'REBRACOVID' - multicentre cohort study of the natural history and immunology of COVID-19 in Brazil funded by GCRF

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2023.102249

PubMed Identifier: 37842172

Publication URI: http://europepmc.org/abstract/MED/37842172

Type: Journal Article/Review

Parent Publication: eClinicalMedicine

ISSN: 2589-5370